unknown by P. B. Sinclair et al.
2000 95: 738-743
 
 
Huntly and A. R. Green
P. B. Sinclair, E. P. Nacheva, M. Leversha, N. Telford, J. Chang, A. Reid, A. Bench, K. Champion, B.
 
poor-prognosis subgroup of patients with chronic myeloid leukemia
Large deletions at the t(9;22) breakpoint are common and may identify a
 
http://www.bloodjournal.org/content/95/3/738.full.html
Updated information and services can be found at:
 (437 articles) Plenary Papers     
Articles on similar topics can be found in the following Blood collections
http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests
Information about reproducing this article in parts or in its entirety may be found online at:
http://www.bloodjournal.org/site/misc/rights.xhtml#reprints
Information about ordering reprints may be found online at:
http://www.bloodjournal.org/site/subscriptions/index.xhtml
Information about subscriptions and ASH membership may be found online at:
  
Copyright 2011 by The American Society of Hematology; all rights reserved.
Hematology, 2021 L St, NW, Suite 900, Washington DC 20036.
Blood (print ISSN 0006-4971, online ISSN 1528-0020), is published weekly by the American Society of
For personal use only. on October 31, 2014.  by guest    www.bloodjournal.org From  For personal use only. on October 31, 2014.  by guest    www.bloodjournal.org From Plenarypaper
Large deletions at the t(9;22) breakpoint are common and may identify a
poor-prognosis subgroup of patients with chronic myeloid leukemia
P. B. Sinclair, E. P. Nacheva, M. Leversha, N. Telford, J. Chang,A. Reid,A. Bench, K. Champion, B. Huntly, andA. R. Green
The hallmark of chronic myeloid leukemia
(CML) is the BCR-ABL fusion gene, which
is usually formed as a result of the t(9;22)
translocation. Patients with CML show con-
siderable heterogeneity both in their pre-
senting clinical features and in the time
taken for evolution to blast crisis. In this
study, metaphase ﬂuorescence in situ
hybridization showed that a substantial
minority of patients with CML had large
deletions adjacent to the translocation
breakpoint on the derivative 9 chromo-
some, on the additional partner chromo-
some in variant translocations, or on both.
The deletions spanned up to several mega-
bases, had variable breakpoints, and could
be detected by microsatellite polymerase
chain reaction in unfractionated bone
marrow and puriﬁed peripheral blood
granulocytes. The deletions were likely to
occur early and possibly at the time of the
Philadelphia (Ph) chromosome transloca-
tion: deletions were detected at diagnosis
in 11 patients, were found in all Ph-positive
metaphases, and were more prevalent in
patients with variant Ph chromosomes.
Kaplan-Meier analysis showed a median
survival time of 36 months in patients
with a deletion; patients without a detect-
able deletion survived . 90 months. The
survival-time difference was signiﬁcant
on log-rank analysis (P 5 .006). Multivari-
ate analysis demonstrated that the prog-
nostic importance of deletion status was
independent of age, sex, percentage of
peripheral blood blasts, and platelet
count. Our data therefore suggest that an
apparently simple, balanced transloca-
tion may result not only in the generation
of a dominantly acting fusion oncogene
but also in the loss of one or more genes
that inﬂuence disease progression.
(Blood. 2000;95:738-744)
r 2000 by The American Society of Hematology
Introduction
Chronic myeloid leukemia (CML) is a clonal hematologic malig-
nant disease arising in the stem-cell compartment.1-3 The hallmark
of CML is the formation of a BCR-ABL fusion gene, usually as a
result of the Philadelphia (Ph) chromosome translocation. The
BCR-ABL fusion gene is thought to play a central role in the
pathogenesis of CML. This concept is strongly supported by
retroviral transduction experiments in which p210 BCR-ABL was
expressed in murine bone marrow cells and resulted in a myelopro-
liferative disorder resembling CML.4-9
CML is a biphasic disease with an initial chronic phase during
which the disorder is readily controlled. However, chronic-phase
CML is followed by a terminal blastic phase that resembles acute
leukemia and is usually refractory to treatment. Transformation of
chronic phase to blast crisis is accompanied by secondary cytoge-
netic changes in approximately 85% of cases.10 However, the
genetic events responsible for the transformation of CML are
poorly understood. Homozygous deletions in the p16Ink gene have
been reported in lymphoid blast crisis.11,12 Mutations in the p53 and
N-ras genes have been reported but are rare.13,14 Allelotype
analysis has identiﬁed loss of heterozygosity at multiple genomic
regions in a varying proportion of patients in blast crisis.15 Some of
these regions may contain tumor suppressor genes that inﬂuence
the evolution to CMLblast crisis.
Current options for treatment of patients with CML include
hydroxyurea, a-interferon (with or without cytosine arabinoside),
and allogeneic or autologous progenitor-cell transplantation. Iden-
tiﬁcation of prognostic factors may be useful in guiding manage-
ment. Patients with CML show considerable clinical heterogeneity
in the chronic phase, and some clinical features, such as spleen size,
blast cell count, and platelet count, have been incorporated into the
Sokal prognostic score.16 The molecular basis for this clinical
variability is not understood but may involve several mechanisms,
including differences in the precise translocation breakpoints of the
Ph chromosome, different genetic background, and environmental
factors that modulate ‘‘competition’’ between normal and malig-
nant stem cells.
The ﬁrst of these possibilities has been investigated in consider-
able detail over the past 10 years and was reviewed by Melo.17 The
position of the translocation breakpoint in the BCR gene alters the
amount of BCR protein in the BCR-ABL fusion protein.This in turn
inﬂuences the phenotype of the associated leukemia, with p190,
p210, and p230 proteins usually accompanying acute lymphoblas-
tic leukemia, CML, and chronic neutrophilic leukemia (CNL),
respectively. It was also reported that the position of the breakpoint
within the M-bcr region may inﬂuence prognosis,18 although larger
studies failed to conﬁrm this idea.19-22 The position of the break-
point relative to the ABL coding sequence is less variable. The few
cases with fusions to the a3 exon seem indistinguishable from those
with the more usual a2 fusion.17 The ABL-BCR fusion gene is
expressed in only about two thirds of patients with CML,23 and the
presence of the ABL-BCR transcript does not inﬂuence cytogenetic
response to interferon.24
We here present the ﬁrst evidence of a previously unrecognized
form of genetic heterogeneity among patients with CML.We found
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genomic deletions resulting in loss of chromosome 9 and 22
sequences ﬂanking the translocation breakpoint on the derivative 9,
on additional partner chromosomes, or on both. Furthermore, such
deletions were associated with a worse prognosis. Our results
suggest that the loss of genes adjacent to the translocation
breakpoint may inﬂuence the progression of CML.
Methods
Patients’clinical and laboratory data
Fixed cytogenetic preparations from cultured bone marrow samples were
obtained from 56 patients with CMLseen between January 1990 and March
1997 in the Department of Hematology at Addenbrooke’s Hospital,
Cambridge, United Kingdom (UK), and in the Department of Oncological
Cytogenetics, Christie’s Hospital, Manchester, UK. Patients who had either
standard (n 5 34) or variant (n 5 22) Ph translocations were included in the
study. The patients were unselected for stage of disease or type of therapy
and were treated at various centers in the Cambridge and Manchester
regions. Risk categories were determined as described previously.16
Fluorescence in situ (FISH) probes and detection systems
Triple-probe/3-color system. This system is based on the following 3
probes (Figure 1): ASS probe, a 350-kilobase (kb) cosmid contig that
contains the ASS gene, the gene 8604 Met (which maps to a region about 20
kb proximal to ABL exon 1b), and the most centromeric breakpoints
reported in patients with CML25; ABL probe (Vysis Inc, Downer’s Grove,
IL), a 300-kb cosmid contig that contains the 38 region of the ABL gene
(ABL exon 3 to the last exon of ABL); and BCR probe (Vysis Inc), an
approximately 300-kb contig that begins between BCR exon 13 and 14 and
extends well beyond the M-bcr region.
As described previously,26 the 3 probes, labeled with Spectrum Green,
Spectrum Orange, and Aqua, were used in combination for FISH experi-
ments to create the triple-probe/3-color BCR-ABL detection system. Images
were captured and pseudocolored to obtain the signal pattern of the original
triple-probe system.
D-FISHBCR-ABLdetectionsystem. Thissystemisavailablecommer-
cially (Appligene Oncor, UK) and consists of the following 2 probes
(Figure 1): ABL probe, a 600-kb contig spanning the breakpoint region on
ABL labeled with a green ﬂuorochrome (ﬂuorescein isothiocyanate, conju-
gated [FITC]); and BCR probe, a 500-kb contig containing the major and
minor breakpoint regions of BCR labeled with a red ﬂuorochrome (Texas
red). Images were captured and analyzed using a Smart Capture View Point
multicolor imaging station (Digital Scientiﬁc, Cambridge, UK), as with the
triple-probe/3-color system.
Chromosome22and9locus-speciﬁcprobes. ThecosmidC106G1220,
isolated from the telomeric region of chromosome 22, was provided by
D. Ledbetter (University of Chicago). All other locus-speciﬁc probes
(cosmids) were obtained from the Sanger Centre, Wellcome Trust Genome
Campus, Hinxton, Cambridgeshire, UK (Figure 5). Approximate distances
between the locus-speciﬁc probes, the BCR gene, and the 22q telomere are
given in Figure 5.27 Distances between the locus-speciﬁc probes from
chromosome 9 used in this study (Figure 5) were based on a physical map
of the 9q34 region.28 C106G1220 and D9S60 were labeled with Spectrum
Orange by using a Vysis nick-translation kit (catalogue 32-801 300). All
other locus-speciﬁc probes were labeled with biotin by using a Gibco-BRL
(Life Technologies, Inc, Gaithersburg, MD) BioNick labeling system
(catalogue 18 247-015). The 2 probes labeled with Spectrum Orange were
used to mark the position of 9q and 22q in metaphase cells. Combinations
of either C106G1220 or D9S60 and each of the biotinylated probes were
applied to cytogenetic preparations from patients known to have deletions
of the region between ABL and ASS. For these experiments, the biotinylated
probe was detected with an avidin/FITC detection system. After capture,
Spectrum Orange signals were pseudocolored in red and FITC signals in
green.
Hybridization and detection procedures
The triple-probe system was dissolved in hybridization buffer to a
concentration of 10 ng/µL for each probe with 200 3 Cot 1 DNA,
denatured, and preannealed as previously described.29 The hybridization
and washing conditions used were those recommended for the Vysis
dual-color BCR-ABL detection system. The Oncor D-FISH and M-bcr/m-
bcr–speciﬁc probes were applied and detected according to the manufactur-
er’s instructions. Combinations of biotinylated and Spectrum Orange–
labeled single-locus probes were denatured with Cot 1 DNA, preannealed,
hybridized, washed, and detected as previously described.30 All FISH
images were captured and analyzed with a Smart Capture View Point
multicolor imaging station (Digital Scientiﬁc). For each marker, consistent
data were obtained from a minimum of 10 Ph-positive metaphase cells in
which the normal chromosomes 9 and 22 displayed normal signal patterns.
Microsatellite polymerase chain reaction (PCR)
Granulocytes andTcells were prepared from peripheral blood as previously
described.31 Microsatellite PCR ampliﬁcation was performed as previously
Figure 1. Structure of ABL and BCR genes and the
probes used in the triple-probe/3-color and D-
ﬂuorescence in situ hybridization (FISH) systems.
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(STS) within intron 14 of the ASS gene32 or to D9S159 (described at
http://www.gdb.org).
Statistical analysis
All calculations were performed with the SPSS statistical package (SPSS
Inc, Chicago, IL). Means and SDs were calculated for age, sex, and clinical
and laboratory ﬁndings at diagnosis for patients with and without deletions
and tested for signiﬁcance with the Mann-Whitney U test (continuous
variables) or x2 analysis and Fisher’s exact tests (categorical variables).
Survival time was calculated from month of presentation to month of death,
with a median follow-up of 23 months (range, 4-90 months). Two patients
who died from transplantation-related complications and one who died in
chronic phase for reasons unrelated to CMLwere censored at date of death.
Survival time in patients with deletions was compared with that in patients
without deletions. Survival data were available for a total of 55 patients.
Values were calculated with the Kaplan-Meier estimator; signiﬁcance was
tested with the log-rank test. The analysis was performed both by time
censoring at the time of transplantation and also by excluding patients who
underwent transplantation. Survival data from the 2 groups of patients were
also used to construct a Cox proportional hazard model from which
signiﬁcance by x2 analysis, hazard ratio, and 95% conﬁdence intervals (CI)
was derived. Possible confounding effects of age, sex, percentage of
peripheral blood blasts, and platelet count on the prognostic importance of
deletion status were assessed with logistic regression analysis.
Results
Deletion of chromosome 9 sequences on the
derivative 9 chromosome
We previously described a triple-probe/3-color FISH system for
detection of BCR-ABL–positive cells.26 The introduction of a probe
for the ASS locus, which lies upstream of ABL, permits identiﬁca-
tion of the derivative 9 chromosome in Ph-positive cells (Figure 1)
and thus allows highly sensitive detection of residual disease.
The normal pattern observed in a Ph-positive metaphase is
shown in Figure 2A. Colocalization of red and blue signals (ABL
and ASS) was seen on the normal chromosome 9 and a single green
signal (BCR) was seen on the normal chromosome 22. In contrast,
colocalization of red and green signals identiﬁed the Ph chromo-
some, and an isolated blue signal was observed on the derivative
chromosome 9. While extending our original observations to a
larger number of patients, we noticed loss of the ASS signal on the
derivative 9 chromosome in 16 of 56 patients with CML (Figure
2B). Deletions of ASS were found in 6 of 34 patients with a
standard Ph chromosome and in 10 of 22 patients with a variant Ph
chromosome. No particular pattern of additional chromosome
involvement was noticed in the patients with variant Ph chromo-
somes. The deletions were observed in diagnostic samples in 11 of
16 patients, indicating that the deletions usually occur early in the
chronic phase of CML.
Deletion of chromosome 22 sequences from the
derivative 9 chromosome
Our study found a loss of chromosome 9 sequences from the
derivative 9 chromosome in a proportion of patients with CML. To
assess whether chromosome 22 sequences were also lost, we used
the D-FISH system (Appligene Oncor).The D-FISH system entails
the use of 2 large probes spanning the translocation breakpoints in
the BCR and ABL loci (Figure 1). The normal pattern observed in a
Ph-positive metaphase is shown in Figure 2C. Colocalized red and
green signals appeared on both the Ph chromosome and the
derivative 9 chromosome. Single red and green signals were seen
on normal chromosome 22 and normal chromosome 9, respec-
tively. In contrast, loss of the colocalized signal on the derivative 9
chromosome was observed in 14 of 16 patients in whom deletion of
ASS was observed (Figure 2D and Figure 5). These data showed
that deletions involving both chromosome 9 and chromosome 22
sequences were present in a substantial minority of patients
with CML.
Figure 2. FISH analysis of Ph-positive metaphase
cells. (A) Triple-probe/3-color signal pattern observed in
a Ph-positive metaphase cell with no detectable deletion
of chromosome 9 sequences. ABL is in red, BCR in
green, and ASS in blue. A colocalized red/green signal
marks the Ph chromosome, the der(9) chromosome is
identiﬁed by a single blue signal, the normal 22 by a
green signal, and the normal 9 by a blue/red doublet. (B)
Triple-probe/3-color signal pattern in a Ph-positive meta-
phase cell with a deletion of chromosome 9 sequences.
The der(9) chromosome does not show a blue ASS
signal (arrow). (C) D-FISH signal pattern in a Ph-positive
metaphase cell with no detectable loss of chromosome 9
or 22 sequences. ABL is in green and BCR in red. A
colocalized red/green signal marks both the Ph and
der(9) chromosomes, a green signal identiﬁes the normal
9, and a red signal marks the normal 22. (D) D-FISH
signal pattern in Ph-positive metaphase with loss of
sequences from chromosome 9 and 22. ABL is in green
and BCR in red. There is a colocalized red/green signal
on the Ph chromosome but not on the der(9) (arrow).
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peripheral blood granulocytes
The Ph chromosome is present in peripheral blood granulocytes in
most patients with chronic-phase CML although, in some, the
percentage of BCR-ABL–positive granulocytes may be signiﬁ-
cantly lower than the percentage of BCR-ABL–positive bone
marrow cells.26We conﬁrmed the existence of the deletion by using
a polymorphic STS that lies within the ASS gene. Loss of
heterozygosity could clearly be seen in bone marrow from a patient
with a deletion (Figure 3A). To investigate whether the deletion
was detectable in peripheral blood cells, we puriﬁed granulocytes
and T cells from 2 other patients, one with and one without a
deletion. Microsatellite PCR using primers for the D9S159 locus,
which lies between D9S115 and D9S63, clearly showed loss of
heterozygosity in granulocytes from the patient in whom our FISH
studies detected a deletion (Figure 3B and Figure 3C).
Size of and variations in deletion breakpoints
To assess the extent of the deletion of chromosome 9 and 22
sequences, we used a panel of locus-speciﬁc FISH probes to map
the deletions in 16 patients found to lack the ASS signal (Figure 4
and Figure 5). For each probe, a minimum of 10 Ph-positive
metaphases were analyzed. For each patient, all metaphases
showed the same hybridization pattern; in no instance did we ﬁnd
clonal variation (ie, some metaphases carrying a deletion and
others lacking a deletion) within the population of Ph-positive
metaphases.
Our results are summarized in Figure 5. Two features are
particularly important. First, deletion breakpoints varied among
patients. Second, the deletions were very large; in some instances,
they spanned several megabases. Contiguous deletion of multiple
markers adjacent to the translocation breakpoint was identiﬁed in
all patients.
Deletion of the derivative 9 chromosome and a poor prognosis
To assess the possible biologic importance of the chromosomal
deletions, we collected data on clinical features, treatment history,
and survival of the patients. Survival data were available for 55
patients (16 with and 39 without detectable deletions).As shown in
Table 1, the clinical and laboratory features at presentation in
patients with and without deletions were not signiﬁcantly different.
However, the median survival time was 36 months (95% CI, 13-60
months) in patients with a deletion and could not be calculated in
patients without a deletion because too many are still alive. The
median follow-up time was similar in patients with and without a
deletion (23.5 months compared with 23 months), as was the range
(4-90 months compared with 7-90 months). The difference in
survival time was signiﬁcant on log-rank analysis (P 5 .006)
(Figure 6). If patients who received a bone marrow transplantation
were excluded, the signiﬁcance level increased (P 5 .004). Signiﬁ-
cance was also obtained with Cox proportional hazard analysis,
with a hazard ratio of 3.81 (95% CI, 1.36-10.73) calculated for
patients with a deletion compared with those without a deletion.
Multivariate analysis showed that the prognostic importance of
deletion status was independent of age, sex, percentage of periph-
eral blood blasts, or platelet count. The only possible confounding
variable was treatment with interferon only: 5 of 16 patients with
deletions but 28 of 40 patients without deletions received this
agent. It seems unlikely that this could have accounted for the
marked survival difference observed here, particularly because
Figure 3. Deletions detectable by microsatellite PCR in bone marrow and
peripheral blood granulocytes. Microsatellite PCR was performed on samples
from 3 different Ph-positive patients by using primers for the loci indicated below each
panel. BM indicates bone marrow; G, granulocytes; and T, T cells. (A) Loss of
heterozygosity at the ASS locus in bone marrow from patient 5. (B) Loss of
heterozygosity at the D9S159 locus in peripheral blood granulocytes from patient 3.
(C) No loss of heterozygosity at the D9S159 locus in granulocytes from a patient with
no detectable deletion.
Figure 4. FISH analysis of deletions by using locus-
speciﬁc probes. Ph-positive metaphases from a patient
with a variant Ph translocation t(9;12;22)(q34;q11;q11)
were hybridized with probes from chromosome 9 (A and
B) or 22 (C and D). (A) C106G1220 (red) and N14A7
(green) signals were observed on both the normal 22 and
derivative 12 chromosome. (B) C106G1220 and N4A10
signals were seen on the normal 22, but only the
C106G1220 signal was detectable on the derivative 12
chromosome. (C) D9S60 (red) and AK1 (green) signals
were observed on both the normal 9 and the derivative 9
chromosome. (d) D9S60 and SPTAN1 signals were seen
on the normal 9 chromosome, but only the D9S60 signal
was detectable on the derivative 9 chromosome.
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interferon.33-36 Furthermore, if our Kaplan-Meier analysis is re-
stricted to patients treated with interferon, although the numbers
are small, patients with deletions have a signiﬁcantly worse
survival time (P 5 .04). Taken together, our results suggest that
large genomic deletions at the translocation breakpoint on the
derivative 9 chromosome are associated with a worse prognosis.
Discussion
We found that a substantial minority of patients with CML had
large deletions adjacent to the translocation breakpoint of the
derivative 9 chromosome. These data show the existence of
previously unsuspected genetic heterogeneity among patients with
CML. We also found evidence suggesting that the large deletions
are associated with a poor prognosis. Our results raise the
possibility that an apparently simple, balanced translocation may
result not only in generation of a dominantly acting fusion
oncogene but also in loss of one or more tumor suppressor genes
adjacent to the translocation breakpoint.
Deletions associated with leukemia translocations have been
described previously. The t(8;21) in one patient was sequenced and
deletions of 5 base pairs (bp) and 18 bp were observed to ﬂank the
translocation breakpoint.37 Analysis of the inv(16) chromosome
has identiﬁed larger deletions (150-350 kb) centromeric to the
short-arm breakpoint,38-41 and partial deletions of MLL sequences
may accompany 11q23 translocation.42
Small deletions of chromosome 22 sequences adjacent to the Ph
chromosome translocation breakpoint have also been identiﬁed (by
Southern blot analysis).43,44 However, these deletions were thought
to be small (about 8-10 kb)43 and without pathophysiologic
importance.44 Indeed, loss of small intronic regions would not
usually be expected to interfere with the splicing events required
for fusion RNAformation.
In contrast, the deletions we observed were large and, in many
cases, spanned several megabases. We detected deletions in 16 of
56 patients, but this ﬁgure may be an underestimate for 2 reasons.
First, the ASS and D-FISH probes are large and may therefore miss
deletions of even 100 to 200 kb. Second, our 16 patients with
deletions were identiﬁed by an initial screening assessment that
looked for the loss of ASS. Our data do not exclude the possibility
Figure 5. Summary of FISH mapping of deletions.
Locus-speciﬁc probes from 9q34.1 and 22q11.2, together
with corresponding genomic27 and physical map28 data,
are shown on the left. White boxes indicate region
retained (2 FISH signals/metaphase cell); black boxes,
region deleted (1 FISH signal/metaphase cell); and gray
boxes, not performed.
Table 1. Patients’characteristics at presentation
Characteristic
Patients With
Deletions
(n 5 16)
Patients Without
Deletions
(n 5 39*)
Sex (M/F) 9/7 23/16
Median age, y (range) 54 (9-75) 47 (17-82)
No. (%) with splenomegaly 8 (50.0) 27 (67.5)
White blood cell count (3109/L) 223 6 180 170 6 129
Hemoglobin (g/L) 101.4 6 19.8 113.1 6 21.1
Platelet count (3109/L) 412 6 273 445 6 258
Peripheral blood blast cells
No. (%) with .2% blast cells 7 (44) 3 (34)
White blood cells (%) 4.79 6 6.64 4.02 6 9.55
No. (%) in blast crisis/accelerated phase
at presentation 2 (12.5) 2 (5.0)
No. (%) in chronic phase 14 (87.5) 38 (95.0)
Sokal high 6 (37.5) 15 (39.5)
Sokal medium 4 (25.0) 9 (26.7)
Sokal low 4 (25.0) 12 (31.6)
Treatment type, no. (%)
Interferon and chemotherapy 5 (31) 28 (70)
Chemotherapy alone 11 (69) 11 (28)
Bone marrow transplantation† 3 (19)† 11 (28)‡
Karyotype, no. (%)‡
Standard Ph 6 (38) 28 (70)
Variant Ph 10 (62) 11 (30)
Additional abnormalities 2 (12.5) 3 (7.5)
Plus 6 minus values are mean 6 SD.
*For hemoglobin, data were obtained for 38 patients; for platelet count, 39
patients; and for .2% blasts, 38 patients. Sokal ratio was calculated for 36 patients.
†Two allogeneic and 1 autologous transplantations were done in patients with
deletions, and 9 allogeneic and 2 autologous transplantations were done in patients
without deletions.
‡Eleven (68%) of patients with deletions and 11 (28%) of those without deletions
had a karyotype analysis at presentation.
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chromosome 22 sequences.
Our data also shed light on the mechanism of the deletions. The
breakpoints were variable, and therefore the deletions did not
reﬂect single recombination hot spots within the chromosome 9
and chromosome 22 sequences on either side of the translocation
breakpoint. The timing of the deletions is not clear. Six of 10 cell
lines derived from patients with blast crisis carried ASS deletions
(unpublished data). This prevalence is higher than what we have
observed in chronic-phase samples and may indicate that deletions
occur as a late event in association with the development of blast
crisis. However, several other observations are consistent with the
idea that deletions arise as an early event: (1) the deletions were
seen in diagnostic samples from 11 patients; (2) in each patient, the
deletion was present in all Ph-positive metaphases analyzed—we
deliberately avoided interphase analysis because of the difficulties
inherent in interpreting the loss of hybridization signals in inter-
phase nuclei; and (3) the prevalence of deletions was higher in
patients with variant Ph chromosomes, and this would be consistent
with a model in which the complex recombination events that occur
during the formation of variant Ph translocations are associated
with an increased probability of deletion. We therefore favor the
idea that the large deletions we identiﬁed occur at the time of the Ph
translocation.Analysis of paired samples from patients at diagnosis
andwithblastcrisiswillbeneededtoconﬁrmorrefutethisconcept.
Our results suggest a signiﬁcant association between the
presence of derivative 9 deletions and a poor prognosis. This
association remained signiﬁcant when the analysis was restricted to
patients who received interferon, although the numbers were small.
These results must be conﬁrmed in a larger study, but could
possibly be the basis for a simple test to identify high-risk patients
who may beneﬁt from more intensive therapy. The use of microsat-
ellite PCR assessment of DNAfrom peripheral blood granulocytes
would even obviate the need for bone marrow aspirations.
How might such genomic deletions inﬂuence the progression of
CML? Several mechanisms can be envisaged.45 In a 2-hit model,
the deletion would result in loss of one copy of a target gene, with
inactivation of the second copy by a subsequent event. The second
event could involve mutation, deletion, or transcriptional silencing
by methylation or imprinting.46,47 Alternatively, loss of only a
single copy of the gene may itself have a pathogenetic role, as has
been shown for p27Kip1.48 A variety of developmental defects in
mice and human beings result from loss of one copy of a particular
gene49-52 or monosomy of particular chromosome regions.53 If
haploinsufficiency for individual genes can perturb fetal develop-
ment, it seems likely that the same mechanism could disrupt
differentiation within adult stem-cell systems such as hemopoiesis.
The large size of the genomic deletions identiﬁed in our study also
raises the possibility that the deletions result in loss of 2 or more
target genes. In this case, inactivation of one or both copies of each
critical gene may be necessary to perturb progenitor-cell behavior.
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